Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Independent of LDL Cholesterol and Statin Use: Results of the Leader Trial
Canadian Journal of Cardiology - Canada
doi 10.1016/j.cjca.2018.07.220
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV